IDXX

Rating buyAI Memo

IDEXX Laboratories

As of 2026-02-03/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-02-03 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Q1 2026 earnings release • 2026-04-30

Expected move: +36%

Biggest risk

Lower-than-expected vet visit volumes, pricing/reimbursement pressure, or failed product rollouts compress revenue and margins toward the analyst low.

Invalidation

Break below $480 or thesis failure.

What would change my mind?

Recurring consumables growth, faster adoption of new diagnostics, and margin expansion push results toward the analyst high; strong execution and stable pricing unlock multiple expansion.

Research note

Recommendation

buy

Confidence

medium

As of

2026-02-03

Base target

$766

p=60%

Bull target

$893

p=20%

Bear target

$480

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 organic revenue and consumables growth
New diagnostic platform rollout / adoption
Recurring consumables growth, faster adoption of new diagnostics, and margin expansion push results toward the analyst high; strong execution and stable pricing unlock multiple expansion.

BearKey bullets

Execution failure on product rollouts and slower consumables conversion
Macro-driven reduction in pet-care visits or discretionary spend
Reimbursement and pricing pressure in veterinary channels

WatchKey bullets

Q1 2026 earnings release

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $766 (p=60%)

Bull/Bear spread: +58% / -15%

Vs latest close: Bull +58% · Base +36% · Bear -15%

Scenario probabilities

Bull Target: $893 (p=20%)Base Target: $766 (p=60%)Bear Target: $480 (p=20%)

Commentary

Consensus is constructive: the analyst median (~$766) sits above the current anchor, implying upside if IDEXX sustains consumables growth and executes on new diagnostics [#SERP-1]. Short-term sentiment is sensitive to the next quarterly print and guidance; market views remain split on adoption timing and margin leverage [#SERP-2].

As of 2026-02-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Recurring consumables growth, faster adoption of new diagnostics, and margin expansion push results toward the analyst high; strong execution and stable pricing unlock multiple expansion.

Bear Case

Lower-than-expected vet visit volumes, pricing/reimbursement pressure, or failed product rollouts compress revenue and margins toward the analyst low.

Drivers

Scannable catalysts and supporting factors

Q1 organic revenue and consumables growth
New diagnostic platform rollout / adoption

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-02-03Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$766.00

Range (USD)

$479.96 - $892.50

Count

Query: IDEXX Laboratories Inc Common (IDXX) analyst consensus price target high low average

IDEXX Laboratories, Inc.: Target Price Consensus and Analysts ...
Search result #1
Mean consensus. OUTPERFORM ; Number of Analysts. 15 ; Last Close Price. 670.46USD ; Average target price. 766.00USD ; Spread / Average Target. +14.25%.
Extracted: $670.46, $766.00Open source
IDEXX Laboratories, Inc. (IDXX) Stock Price, News, Quote & History
Search result #2
IDEXX LABORATORIES INC has an Investment Rating of BUY; a target price of $755.000000; an Industry Subrating of High; a Management Subrating of High; a Safety ...
Extracted: $755.00Open source
IDEXX Labs (IDXX) Stock Forecast & Price Target - Investing.com
Search result #3
According to projections from 13 analysts, the average 12-month price target for IDEXX Labs is 766.00, with a high estimate of 850 and a low estimate of 470 ...
Open source
IDXX: IDEXX Laboratories - Price & Consenus Chart - Zacks.com
Search result #4
IDXX 713.35 +0.96(0.13%). Will IDXX be a Portfolio Killer in January? Zacks Investment Research is releasing its prediction for IDXX based on the 1-3 month ...
Open source
IDXX / IDEXX Laboratories, Inc. (NasdaqGS) - Forecast, Price Target ...
Search result #5
The average one-year price target for IDEXX Laboratories, Inc. is $783.52. The forecasts range from a low of $479.96 to a high of $892.50. Read More.
Extracted: $783.52, $479.96, $892.50Open source
Idexx Laboratories stock forecast - IDXX - TipRanks
Search result #6
The average price target is $792.78 with a high forecast of $850.00 and a low forecast of $750.00. The average price target represents a 14.11% change from the ...
Extracted: $792.78, $850.00, $750.00Open source

Scenarios

Bull Target (Scenario probability)

$893 / p=20% prob

Base Target (Scenario probability)

$766 / p=60% prob

Bear Target (Scenario probability)

$480 / p=20% prob

Price $564 as of 2026-05-29

Nearest Scenario: Bear (∆ 15%)

Targets vs latest close: Bull +58% · Base +36% · Bear -15%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-04-30
Q1 2026 earnings release
Earnings/date not formally announced; using company historical timing (late-April) as the assumed window end — results and guidance will drive a clearer directional move [#SERP-2].
Prob 70.00% • Move 12.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Q1 organic revenue and consumables growth
2026-05-04
Q1 results (company pattern: late-April announcement) could show recurring consumables growth and margin leverage versus expectations, providing a short-term upside catalyst [#SERP-2].
Prob 45% • Move 8% • Priced-in 60%

Long-term Catalysts

Months to a year

New diagnostic platform rollout / adoption
2027-02-03
Successful commercial rollout or regulatory/technical milestones for next-gen diagnostics could materially expand addressable market and margins over the next year [#SERP-3].
Prob 30% • Move 25% • Priced-in 20%

Risks

Execution failure on product rollouts and slower consumables conversion
Macro-driven reduction in pet-care visits or discretionary spend
Reimbursement and pricing pressure in veterinary channels

Peers

Symbol	Summary
ZTS	Zoetis — large animal-health leader; scale and global distribution provide a useful contrast to IDEXX's lab- and consumables-led model.
TMO	Thermo Fisher Scientific — broad diagnostics and lab tools exposure; useful comp for technology adoption, pricing dynamics, and consumables economics.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: IDEXX Laboratories Inc Common (IDXX) analyst consensus price target high low average
Analysis date: 2026-02-03

AI Stock Memo: IDXX - IDEXX Laboratories - RankAlpha